{'fraction_non_alphanumeric': 0.018292682926829267, 'fraction_numerical': 0.0040650406504065045, 'mean_word_length': 4.863095238095238, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mending broken hearts: the future of drug-based cardiac regeneration.

Coronary heart disease is a massive health problem worldwide. In the USA alone, 1.2 million people suffer a coronary attack every year, and approximately 40% of these individuals die as a result. As damaged cardiac muscle forms scar tissue and is unable to function properly, those that do survive the attack are often left severely ill. Consequently, the potential for a therapy that allows healthy cardiac muscle to proliferate at the site of injury is enormous. Dr Mark Keating is a leading researcher in this area of regenerative medicine and his group has recently identified a compound that aids in the process of cardiac regeneration. Although currently focussing on ophthalmic drug research at Novartis, Dr Keating still has a great interest in this area. Here he discusses the potential of drug-based cardiac regeneration and the problems that must be overcome before this treatment can reach the clinic.